11 result(s) for Adolescent and Young Adult (AYA)
| PI Name | Protocol # | Title |
|---|---|---|
| Sancy Leachman | IRB00010561 | War on Melanoma: Enlisting a cohort of melanoma survivors and their families |
| Brandon Hayes-Lattin | IRB00011960 | Long-Term Follow-Up of Patients Exposed to Lentiviral- Based CAR T-Cell Therapy |
| Lara Davis | IRB00012039 | Sarcoma Survivorship Registry |
| Sancy Leachman | STUDY00015038 | Melanoma Tissue Bank Consortium: A Multi-Center Repository of Biospecimens and Data for Future Use |
| Brandon Hayes-Lattin | STUDY00019250 | [NCI CIRB] A041501: A Phase III Trial To Evaluate the Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All |
| Eneida Nemecek | STUDY00020379 | Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
| Michael Heinrich | STUDY00021884 | An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) |
| Lara Davis | STUDY00022158 | SARC038: A Phase 2 Study of Regorafenib in Combination with Nivolumab in Patients with Refractory or Recurrent Osteosarcoma |
| Evan Shereck | STUDY00023290 | [NMDP IRB-MOU] Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases |
| Jessica Leonard | STUDY00024260 | Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant |
| Deanne Tibbitts | STUDY00025328 | Investigating sex and gender-related differences in immunotherapy treatment effects |
You may also qualify for Phase 1 Program trials.